Search results for "leukemia."

showing 10 items of 970 documents

Setil:Italian multicentric epidemiological study on risk factors for childhood leukemia, non Hodgkin lymphoma and neuroblastoma

2008

epidemiology risk factors leukemiaSettore MED/42 - Igiene Generale E Applicata
researchProduct

Evaluation of fitness levels of children with a diagnosis of acute leukemia and lymphoma after completion of chemotherapy and autologous hematopoieti…

2014

The aim of this study was to assess the fitness levels and possible deficits in physical performance in children with a diagnosis of childhood acute leukemia and lymphoma after 10 months of therapy ending through a specific test battery. A total of 58 subjects were enrolled in this study. The experimental group (EG) (7.55 ± 2.43 years; 41.8 ± 16.37 kg; 144.6 ± 10.21 cm) consisted of 18 children with diagnosed leukemia and lymphoma after completion of 10 months of therapy intervention and 40 healthy children who were enrolled in a control group (CG) (7.92 ± 1.78 years; 37.4 ± 12.37 kg; 140.6 ± 12.61 cm). A testing battery including the standing broad jump; the sit-up test; the 4 × 10 m shutt…

fitness testsMaleMulti-stage fitness testCancer Researchmedicine.medical_specialtyTransplantation Conditioningfitness testLymphomamedicine.medical_treatmentPhysical fitnessHematopoietic stem cell transplantationTransplantation AutologousInternal medicineHumansMedicineRadiology Nuclear Medicine and imagingChildOriginal ResearchCancerAcute leukemiafitneLeukemiabusiness.industryHematopoietic Stem Cell TransplantationCase-control studymedicine.diseasefitnessLymphomaTest (assessment)LeukemiaOncologyPhysical FitnessCase-Control StudiesAcute DiseaseExercise TestPhysical therapyFemalebusinessCancer Medicine
researchProduct

Cytotoxicity of 91 Kenyan indigenous medicinal plants towards human CCRF-CEM leukemia cells.

2015

Abstract Ethnopharmacological relevance Plants from Kenyan flora are traditionally used against many ailments, including cancer and related diseases. Cancer is characterized as a condition with complex signs and symptoms. Recently there are recommendations that ethnopharmacological usages such as immune and skin disorders, inflammatory, infectious, parasitic and viral diseases should be taken into account when selecting plants that treat cancer. Aim The present study was aimed at investigating the cytotoxicity of a plethora of 145 plant parts from 91 medicinal plants, most of which are used in the management of cancer and related diseases by different communities in Kenya, against CCRF-CEM …

food.ingredientCell Survival01 natural sciences03 medical and health sciences0302 clinical medicinefoodCell Line TumorDrug DiscoveryHumansMedicinal plantsCytotoxicityPharmacologyLeukemiaPlants MedicinalbiologyTraditional medicinePlant ExtractsZanthoxylum gilletiiSolanum aculeastrumBridelia micranthabiology.organism_classificationAntineoplastic Agents PhytogenicKenyaGrowth Inhibitors0104 chemical sciences010404 medicinal & biomolecular chemistry030220 oncology & carcinogenesisHerbvisual_artvisual_art.visual_art_mediumBarkErythrina sacleuxiiJournal of ethnopharmacology
researchProduct

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenou…

2010

Abstract Imatinib mesylate (imatinib), a competitive inhibitor of the BCR-ABL tyrosine kinase, is highly effective against chronic myelogenous leukemia (CML) cells. However, because 20–30% of patients affected by CML display either primary or secondary resistance to imatinib, intentional activation of Vγ9Vδ2 T cells by phosphoantigens or by agents that cause their accumulation within cells, such as zoledronate, may represent a promising strategy for the design of a novel and highly innovative immunotherapy capable to overcome imatinib resistance. In this study, we show that Vγ9Vδ2 T lymphocytes recognize, trogocytose, and efficiently kill imatinib-sensitive and -resistant CML cell lines pre…

gamma delta T cells Imatinib Leukemia cellsAdultmedicine.medical_treatmentImmunologyMice SCIDLymphocyte ActivationZoledronic AcidPiperazinesMicehemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineImmunology and AllergyAnimalsHumansneoplasmsCells CulturedDiphosphonatesbusiness.industryImidazolesImatinibReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.diseaseIn vitroCoculture TechniquesDrug Resistance MultipleLeukemiaImatinib mesylatePyrimidinesCell cultureDrug Resistance NeoplasmImmunologyBenzamidesCancer researchImatinib MesylatebusinessK562 CellsTyrosine kinasemedicine.drugChronic myelogenous leukemiaT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Antiproliferative and proapoptotic activities of hydroxytyrosol derivates on human promyelocytic leukemia cell lines.

2012

hydroxytyrosol antiproliferative proapoptotic promyelocytic leukemia cell lines.Settore BIO/09 - Fisiologia
researchProduct

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias

2018

γδ T lymphocytes are potent effector cells, capable of efficiently killing tumor and leukemia cells. Their activation is mediated by γδ T-cell receptor (TCR) and by activating receptors shared with NK cells (e.g., NKG2D and DNAM-1). γδ T-cell triggering occurs upon interaction with specific ligands, including phosphoantigens (for Vγ9Vδ2 TCR), MICA-B and UL16 binding protein (for NKG2D), and PVR and Nectin-2 (for DNAM-1). They also respond to cytokines undergoing proliferation and release of cytokines/chemokines. Although at the genomic level γδ T-cells have the potential of an extraordinary TCR diversification, in tissues they display a restricted repertoire. Recent studies have identified …

lcsh:Immunologic diseases. Allergy0301 basic medicineαβ T-cellChemokineB-cell depletion; hematopoietic stem cells; HLA-haploidentical transplantation; receptors; αβ T-cell; γδ T-cellsReceptors Antigen T-Cell alpha-betaMini ReviewHLA-haploidentical transplantationImmunologyGenes MHC Class Ichemical and pharmacologic phenomenaMajor histocompatibility complexCD19Mice03 medical and health sciencesγδ T-cellsAntigenReceptorsMHC class ImedicineAnimalsHumansImmunology and AllergyIntraepithelial LymphocytesB-LymphocytesLeukemiaB-cell depletionbiologyT-cell receptorHematopoietic Stem Cell Transplantationmedicine.diseaseNKG2DKiller Cells NaturalLeukemia030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACytomegalovirus InfectionsImmunologybiology.proteinlcsh:RC581-607Hematopoietic stem cellsFrontiers in Immunology
researchProduct

In Vitro Modulation of P-Glycoprotein Activity by Euphorbia intisy Essential Oil on Acute Myeloid Leukemia Cell Line HL-60R

2021

Euphorbia species have a large spectrum of traditional medicinal uses. We tested the biological activities of the essential oil (EO) of Euphorbia intisy Drake in an acquired multidrug resistance leukemia model to assess whether the EO obtained by hydrodistillation of stems was able to reverse the resistant phenotype. HL-60R cell lines are characterized by the overexpression of P-glycoprotein (P-gp), inhibitors of apoptosis proteins (IAPs) and constitutive expression of NF-κB. EO chemical composition was determined by GC/MS analysis

lcsh:Medicinelcsh:RS1-441Pharmaceutical ScienceP-glycoprotein01 natural sciencesessential oilNF-κBFlow cytometrylcsh:Pharmacy and materia medicamultidrug resistanceDrug DiscoverymedicineChemosensitizing agentSettore BIO/15 - Biologia FarmaceuticaP-glycoproteincancer cellbiologymedicine.diagnostic_test010405 organic chemistryChemistrylcsh:RMyeloid leukemiamyeloid leukemia cellSettore CHIM/08 - Chimica FarmaceuticaMolecular biologyIn vitro0104 chemical sciencesMultiple drug resistance010404 medicinal & biomolecular chemistryApoptosisCell cultureSettore BIO/03 - Botanica Ambientale E ApplicataSettore BIO/14 - Farmacologiabiology.proteinMolecular Medicineinhibitors of apoptosis proteinsPharmaceuticals
researchProduct

A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.

2015

Background: Na+/H+ exchanger-1 (NHE-1) is involved in pH regulation and is up-regulated in different malignancies. Activation of NHE-1 is one way for allowing cells to avoid intracellular acidification and protect them against apoptosis. Inhibitors of NHE-1 are able to decrease intracellular pH and induce apoptosis. Some statins can also act by partial inhibition of NHE-1. This review presents progress in understanding the mechanisms of action of these inhibitors, connections with certain genetic mutations and acquired treatment resistance, as well as new patents on them. Methods: A MEDLINE search for original and review articles using key terms, Na+/H+ exchanger, leukemia, cariporide, and …

lovastatinlcsh:MedicineApoptosisPharmacologyGuanidinesAmiloridep-glycoproteinhemic and lymphatic diseasesDrug InteractionsSulfonesCation Transport ProteinsSodium-Hydrogen Exchanger 1leukemiaMyeloid leukemiaHydrogen-Ion ConcentrationSorafenibUp-RegulationLeukemiaLeukemia Myeloid AcuteImatinib MesylateSignal transductionTyrosine kinasemedicine.drugSignal TransductionSorafenibNiacinamideisoprenylationSodium-Hydrogen Exchangersbcr/ablAntineoplastic AgentsGenes ablGeneral Biochemistry Genetics and Molecular BiologystatinsPatents as TopicCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorscariporidena+/h+ exchangerTumor hypoxiabusiness.industryPhenylurea Compoundslcsh:ROsmolar Concentrationintracellular phmedicine.diseaseImatinib mesylatefms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3MutationCancer researchTumor Hypoxiaflt3/itdHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessHeme Oxygenase-1DNA DamageBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia

2021

Simple Summary Although the prognosis of acute lymphoblastic leukemia (ALL) has improved significantly during the past decades, ALL remains a major cause of pediatric cancer mortality, and more accurate risk-stratification is required. We investigated IGF2BP3, which has previously been associated with aggressive cancers, and found high and subtype-specific expression of IGF2BP3 in B-cell ALL, that was associated with good outcome in high-risk patients. Results suggest that IGF2BP3 could be useful to improve stratification and prognosis of B-ALL. Abstract The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved i…

lähetti-RNAmRNAproliferation3122 Cancersleukemiabiomarkkeritennusteetlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)lcsh:RC254-282Articleinsulin-like growth factor 2 mRNA-binding protein 3 (<i>IGF2BP3</i>)akuutti lymfaattinen leukemiapediatric B-cell acute lymphoblastic leukemia1182 Biochemistry cell and molecular biologysyöpätauditproteiinitprognosisproteinCancers
researchProduct